PMID- 36281099
OWN - NLM
STAT- MEDLINE
DCOM- 20221026
LR  - 20221118
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 42
DP  - 2022 Oct 21
TI  - Two-dimensional speckle tracking echocardiography, a powerful method for the 
      evaluation of anthracyclines induced left ventricular insufficiency.
PG  - e31084
LID - 10.1097/MD.0000000000031084 [doi]
LID - e31084
AB  - Anthracyclines have been one of the most important therapeutic methods in breast 
      cancer therapy for decades. However, serious long-term toxicities, especially 
      cardiotoxicity limits the continuous usage of anthracyclines, hence affects long 
      term prognosis. Early detection of myocardial dysfunction during treatment is 
      critical but challenging. Two-dimensional speckle tracking echocardiography 
      (2D-STE) is a non-Doppler technique that can assess deformation and strain by 
      tracking displacement of acoustic markers in the myocardium. This study aims to 
      compare the sensitivity and precision between 2D-STE and traditional 
      echocardiography on monitoring the left ventricular function in patients with 
      breast cancer after anthracyclines therapy, which is the key indicator for 
      evaluating myocardial changes. Thirty-three patients with breast cancer were 
      recruited from February 2019 to December 2019. All patients were treated with 4 
      cycles anthracycline. 2D-STE and conventional echocardiography were performed on 
      each patient. Two-dimensional echocardiographic examination was used to collect 
      data interventricular septum diameter (IVSD), end-diastolic left ventricular 
      posterior wall diameter (LVPWD), left ventricular end-diastolic diameter (LVEDD) 
      and left ventricular systole on the parasternal left ventricular long axis view. 
      The final diameter (left ventricular end-systolic diameter [LVESD]) and the left 
      ventricular short axis shortening rate (LVFS) was measured by M-type. The 
      two-plane Simpson's method was used to measure left ventricular end-diastolic 
      volume (LVEDV) and end-systolic volume (left ventricular end-systolic volume 
      [LVESV]) to obtain left ventricular ejection fraction (LVEF). Two-dimensional 
      speckle tracking imaging technical indicator includes left ventricular global 
      longitudinal strain (LVGLS), subendocardial myocardial longitudinal strain 
      (LVGLS-Endo) and epicardial myocardial longitudinal strain (LVGLS-Epi). The 
      correlation between 2-dimensional speckle tracking imaging and conventional 
      ultrasound parameters were analyzed. Compared with baseline (T0), the systolic 
      function parameter LVEF was significantly changed after four cycle chemotherapy 
      (T4) (P < .05). However, the conventional echocardiographic parameters including 
      IVSD, LVPWD, LVEDD, LVESD, LVEDV, and LVESV were not statistically significant (P 
      > .05). Meanwhile, the two-dimensional strain parameters LVGLS, LVGLS-Endo, and 
      LVGLS-Epi were statistically significant after T2 and T4 cycle chemotherapy (P < 
      .01).The two-dimensional strain parameter GLS has higher accuracy and sensitivity 
      for monitoring left ventricular insufficiency caused by anthracycline therapy 
      when compared with traditional echocardiography.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Chen, Wei
AU  - Chen W
AD  - The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, 
      China.
FAU - Jiao, Ziyi
AU  - Jiao Z
FAU - Li, Wenjie
AU  - Li W
FAU - Han, Ruoling
AU  - Han R
AUID- ORCID: 0000-0003-0954-2386
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anthracyclines)
RN  - 0 (Antibiotics, Antineoplastic)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Anthracyclines/adverse effects
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - Early Detection of Cancer
MH  - Echocardiography/methods
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - *Breast Neoplasms/drug therapy/chemically induced
PMC - PMC9592473
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/10/26 06:00
MHDA- 2022/10/27 06:00
PMCR- 2022/10/21
CRDT- 2022/10/25 01:15
PHST- 2022/10/25 01:15 [entrez]
PHST- 2022/10/26 06:00 [pubmed]
PHST- 2022/10/27 06:00 [medline]
PHST- 2022/10/21 00:00 [pmc-release]
AID - 00005792-202210210-00022 [pii]
AID - 10.1097/MD.0000000000031084 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Oct 21;101(42):e31084. doi: 
      10.1097/MD.0000000000031084.